Our community narratives are driven by numbers and valuation.
Below is a sell-side / investment banking style investment memo on Village Farms International (NASDAQ: VFF), fully based on the Q1 2026 results and FY2025 10-K annual report , with verified data points and citations. Village Farms International (VFF) – Investment Memo Date: May 2026 Executive Summary Village Farms International (“Village Farms” or the “Company”) is a vertically integrated, low-cost cannabis producer with a differentiated heritage in Controlled Environment Agriculture (CEA).Read more
Jarir Marketing continues to show a stable financial profile, supported by strong brand positioning, steady profitability, and a high dividend payout policy. The company reported revenue of SAR 11.45bn in 2025, compared with SAR 10.91bn in 2024, while net profit reached SAR 1.05bn.Read more
Blackrock Silver is chasing a high-quality silver and gold find in Nevada, with early work suggesting the deposit could be much bigger than the market expects if drilling keeps delivering. But it’s still years away from proving it can become a real mine, and delays, new fundraising, or weaker metal prices could quickly change the story.Read more

Archer Aviation is positioned to be the first to scale in the trillion-dollar Urban Air Mobility (UAM) market. Unlike competitors struggling with "production hell," Archer has solved the manufacturing equation through its strategic partnership with Stellantis , which is funding and building Archer's high-volume factory in Georgia.Read more
The Valuation Model: The Math Behind the $6.65 Target Our valuation is built on a theoretical 2031 "Bull Case" scenario, assuming the successful execution of Commercial Phase 1 and the initiation of Phase 2 at the Fort Cady facility. 2031 Projected Revenue: $550,000,000 USD (Driven by core boric acid production and a ~20% shift into high-margin advanced derivatives like Meta Boric Acid and Ferroboron).Read more
Take-Two leans heavily on the next Grand Theft Auto, with pre-orders and fresh updates expected soon and a launch set for the holiday season. The big question is whether demand lives up to the hype—or whether another delay or a crowded games market spoils what could be a major turning point for the company.Read more

A softer start to the year masks a business that still leans on renewable energy projects and a large backlog of work that management says should pick up as the year goes on. A new tie-up to blend biomass with existing gas networks and growing demand in Indonesia could open fresh, repeat business, but the company still has to navigate global disruption and swinging exchange rates.Read more
Below is a fact-checked, integrated investment memo on Paradigm Biopharmaceuticals (ASX: PAR), made with copilot help, (if you find any errors, please let me know); combining validation of AmirV claims with external sources and a professional investment framework. Investment Memo: Paradigm Biopharmaceuticals (ASX: PAR) Ticker: PAR (ASX) Sector: Biotechnology (Late-stage clinical) Core Asset: Zilosul® (injectable pentosan polysulfate sodium, PPS) Date: May 2026 1.Read more